The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013

被引:21
|
作者
Park, Sun-Kyeong [1 ]
Baek, Yeon-Hee [1 ]
Pratt, Nicole [2 ]
Ellett, Lisa Kalisch [2 ]
Shin, Ju-Young [1 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, 300 Cheonchoen Dong, Suwon 440746, Gyeonggi Do, South Korea
[2] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia
基金
新加坡国家研究基金会;
关键词
RECEPTOR ANTAGONIST USE; ALZHEIMERS-DISEASE; INCIDENT DEMENTIA; STATIN USE; VITAMIN-B-12; METAANALYSIS; MEDICATION; COHORT; BIAS;
D O I
10.1007/s40264-018-0638-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Studies have found an association between the use of proton pump inhibitors (PPIs) and dementia, but these findings may have been confounded by selection biases. We used prescription sequence symmetry analysis (PSSA) to estimate the sequence ratio (SR) between PPI use and dementia compared with an active comparator, the use of histamine-2 receptor antagonists (H2RAs). We conducted a PSSA on a nationwide South Korean database between 2002 and 2013. Exposure was defined as new PPI users, and outcome was defined as a new dementia diagnosis (International Statistical Classification of Diseases and Related Health Problems, 10th revision [ICD-10] codes F00-03, F05.1, G30, G31.1, G31.9, G31.82). In this study, we applied the 3-year time window. So the patients who initiated PPIs 3 years before or after their first diagnosis of dementia were included. The pairs with the time window < 6 months were excluded to minimize the potential protopathic bias. The SR was calculated as the number of patients first diagnosed with dementia after initiating PPI (causal group) divided by the number of patients first diagnosed with dementia before the initiation of PPI (non-causal group). The SR was adjusted (aSR) to avoid the distortion of results due to underlying trends in PPI use and dementia diagnosis over time. We calculated 95% confidence intervals (CIs) for the aSR. The analysis was repeated for initiators of H2RAs. Sensitivity analyses were conducted using 1-, 2-, and 6-year time windows and using the initiation of medication for dementia treatment (Anatomical Therapeutic Chemical code: N06D). Our results showed that the aSR of dementia and PPIs (7342 pairs, aSR 1.21 [95% CI 1.16-1.27]) was not higher than that for dementia and H2RAs (6170 pairs, aSR 1.91 [95% CI 1.80-2.02]). When we used various time windows and restricted the findings to the use of medication for treating dementia, the results were consistent with the main results. The risk of PPIs being associated with dementia may be overestimated. Further pharmacoepidemiological studies are needed to identify the risk of dementia with PPI use.
引用
收藏
页码:615 / 624
页数:10
相关论文
共 11 条
  • [1] Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia
    Park, Sun-Kyeong
    Nam, Jin Hyun
    Lee, Hyesung
    Chung, Hyunsoo
    Lee, Eui-Kyung
    Shin, Ju-Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (12) : 2135 - 2143
  • [2] No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis
    Hussain, Salman
    Singh, Ambrish
    Zameer, Saima
    Jamali, Mohammad Chand
    Baxi, Harveen
    Rahman, Syed Obaidur
    Alam, Mahtab
    Altamish, Mohammad
    Singh, Avinash Kumar
    Anil, Dasari
    Hussain, Md Sarfaraj
    Ahmad, Adil
    Najmi, Abul Kalam
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (01) : 19 - 28
  • [3] Signal detection of benzodiazepine use and risk of dementia: sequence symmetry analysis using South Korean national healthcare database
    Park, Kyung-Rock
    Kim, Kyu-Beom
    Baek, Yeon-Hee
    Sung, Hi Gin
    Park, Jung-Tae
    Lee, Eui-Kyung
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (06) : 1568 - 1576
  • [4] Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study
    Hwang, In Cheol
    Chang, Jooyoung
    Park, Sang Min
    PLOS ONE, 2018, 13 (09):
  • [5] Association between proton pump inhibitor use and the risk of hepatobiliary cancers: A meta-analysis
    Yi, Tai-Yung
    Peng, Tzu-Rong
    Wu, Ta-Wei
    Wu, An-Jan
    ADVANCES IN DIGESTIVE MEDICINE, 2024, 11 (03) : 151 - 161
  • [6] No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease
    Taipale, Heidi
    Tolppanen, Anna-Maija
    Tiihonen, Miia
    Tanskanen, Antti
    Tiihonen, Jari
    Hartikainen, Sirpa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (12) : 1802 - 1808
  • [7] The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis
    Nochaiwong, Surapon
    Ruengorn, Chidchanok
    Awiphan, Ratanaporn
    Koyratkoson, Kiatkriangkrai
    Chaisai, Chayutthaphong
    Noppakun, Kajohnsak
    Chongruksut, Wilaiwan
    Thavorn, Kednapa
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (02) : 331 - 342
  • [8] Association between proton pump inhibitor use and migraine: a systematic review and meta-analysis
    Satapathy, Prakasini
    Khatib, Mahalaqua Nazli
    Vadia, Nasir
    Menon, Soumya V.
    Chennakesavulu, Kattela
    Panigrahi, Rajashree
    Shabil, Muhammed
    Singh, Mahendra
    Sah, Sanjit
    Lingamaiah, Doddolla
    Goh, Khang Wen
    Mawejje, Edward
    Bushi, Ganesh
    JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01)
  • [9] Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals
    Nhi Thi Hong Nguyen
    Huang, Chih-Wei
    Wang, Ching-Huan
    Lin, Ming-Chin
    Hsu, Jason C.
    Hsu, Min-Huei
    Iqbal, Usman
    Nguyen, Phung-Anh
    Yang, Hsuan-Chia
    CANCERS, 2022, 14 (24)
  • [10] Impact of Medication Adherence on the Association Between Oral Anticoagulant Use and Risk of Dementia: A Retrospective Cohort Study using the Japanese Claims Database
    Komatsu, Yuika
    Yokoyama, Satoshi
    Hosomi, Kouichi
    Takada, Mitsutaka
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 437 - 449